MedImmune's Biologic Solution To Blocking IGF In Solid Tumors Heads Into Phase II Studies

MIDI-573, which blocks insulin-like growth factor I and II while sparing receptors for normal glucose processing, heads into multiple Phase II studies this year accompanied by an assay to prospectively identify patient populations for further study, MedImmune head of oncology McMahon said in an April 4 interview at AACR.